XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 05, 2021
Mar. 31, 2022
Commitments And Contingencies [Line Items]    
Contingent milestones commitments recognized   $ 0
Research and development expense for termination   $ 800,000
Estimated service fees and pass-through expenses $ 33,000,000  
Active Pharmaceutical Ingredients [Member]    
Commitments And Contingencies [Line Items]    
Agreement description   Under a manufacture and supply agreement with the active pharmaceutical ingredients (“API”) manufacturer for molgramostim, Savara must make certain payments to the API manufacturer upon achievement of the milestones outlined in the table set forth below. Additionally, upon first receipt of marketing approval by Savara from a regulatory authority in a country for a product containing the API for therapeutic use in humans and ending the earlier of (i) ten years thereafter or (ii) the date a biosimilar of such product is first sold in such country, Savara shall pay the API manufacturer a royalty equal to low-single digits of the net sales in that country.
Nebulizer [Member]    
Commitments And Contingencies [Line Items]    
Royalty percent on net sale   3.50%